Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Otsuka Holdings Co Ltd's Subsidiary Obtains Marketing Approval in Japan for Onglyza Tablets to Treat Type 2 Diabetes; Transfers Rights to Kyowa Hakko Kirin Co., Ltd


Monday, 25 Mar 2013 02:30am EDT 

Otsuka Holdings Co Ltd announced that its subsidiary, Otsuka Pharmaceutical Co., Ltd., has obtained marketing approval for Onglyza Tablets 2.5mg and 5mg(generic name: saxagliptin hydrate) to treat type 2 diabetes. Otsuka signed an agreement with Kyowa Hakko Kirin Co., Ltd in June 2012, transferring to Kyowa Hakko Kirin the exclusive development and marketing rights for Onglyza in Japan. 

Company Quote

3619.0
-27.5 -0.75%
4 Mar 2015